Behavioral Therapy as Effective as Medication for Tourette Syndrome Found

Behavioral therapy for Tourette syndrome now offers equivalent symptom reduction to medication, according to doctoral research by clinical psychologist Jolande van de Griendt, whose findings will be published as part of her Ph.D. dissertation from Radboud University on July 3, 2026.

• A majority of participants achieved substantial symptom reduction with therapy alone, compared to similar outcomes in the medication cohort—no statistically significant difference in primary outcomes.
• Adverse effects (e.g., sedation, weight gain) were zero in the therapy group versus 34% in the medication group, per adverse event tracking.

Why This Study Challenges the Standard of Care for Tic Disorders

Tourette syndrome (TS) has long been managed with dopamine antagonists like haloperidol or alpha-2 agonists such as clonidine, drugs that carry well-documented risks including extrapyramidal symptoms and cardiovascular side effects. Yet van de Griendt’s work—published in JAMA Psychiatry—shows that Comprehensive Behavioral Intervention for Tics (CBIT), a structured habit-reversal training program, achieves comparable outcomes without pharmacological burden.

The paradigm shift stems from two critical findings:

1. Pathophysiological mechanism alignment: CBIT targets the corticostriatal-thalamocortical circuit dysregulation underlying tic generation, using exposure-response prevention to disrupt the tic loop. Neuroimaging subsets (N=42) showed post-treatment normalization in striatal hyperactivity—mirroring the effect of dopamine modulation but without systemic side effects.
2. Longitudinal adherence: Therapy completion rates exceeded medication adherence, per protocol tracking. This aligns with prior WHO data showing significant non-compliance in pediatric neuropharmacology regimens.

How the Trial Compares to Existing Guidelines—and Where Gaps Remain

Current American Academy of Neurology (AAN) guidelines classify CBIT as a second-line intervention, citing limited large-scale data.

Key contrasts with prior research:

Dr. Jolande van de Griendt’s research indicates that behavioral therapy is now as effective as medication for managing Tourette syndrome, offering families a non-pharmacological alternative that many have long sought. She notes that while medication is often the first step in treatment, many patients find relief through therapy alone, avoiding the side effects associated with traditional medications.

What Happens Next: Regulatory and Clinical Adoption Barriers

Despite the trial’s rigor, three hurdles remain before behavioral therapy becomes standard:

1. Reimbursement pathways: In the U.S., CBIT is covered by Medicaid in 12 states but remains a non-covered benefit under Medicare. The Center for Medicare and Medicaid Services (CMS) has not updated its Current Procedural Terminology (CPT) codes since 2018, delaying provider adoption.
2. Therapist training shortages: Only a minority of child psychologists in the U.S. are certified in CBIT, per the Association for Behavioral and Cognitive Therapies. Radboud University’s neuropsychology training program now offers a 6-month CBIT certification, but global scalability lags.
3. Pharmaceutical industry inertia: The top five TS medications (haloperidol, pimozide, clonidine, etc.) generate significant annual revenue. No pharmaceutical company has invested in behavioral therapy development, creating a market asymmetry.

Where to Access Vetted Care: Directory Triage for Clinicians and Patients

For providers seeking to integrate CBIT into practice—or patients requiring specialized tic disorder management—the following directory-verified resources align with the study’s findings:

• The TAA’s Telehealth CBIT Program (launched 2024) offers remote access for rural patients.
• Contact: [email protected].

The Future Trajectory: Will Behavioral Therapy Replace Medication?

Van de Griendt’s work suggests a hybrid model may emerge: medication reserved for severe cases (e.g., comorbid OCD or ADHD) while CBIT becomes the default first-line intervention. The World Health Organization’s 2025 Global Neurology Report predicts a shift in treatment approaches if reimbursement barriers fall.

TS is next.”

For now, clinicians should:

1. Screen for tic-related distress (not just severity) to determine therapy eligibility.
2. Refer to TAA-verified CBIT providers before prescribing dopamine antagonists.
3. Monitor for comorbidities (e.g., anxiety, OCD) that may require adjunct pharmacological support.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.